Every article, presentation, spotlight, and news item we've tagged to Metabolic Pathways.
Showing 73–79 of 79
Iron accumulation drives a coordinated aging process called ferro-aging through oxidative damage and lipid peroxidation; vitamin C reverses these markers in primate models. This identifies iron metabolism and lipid oxidation as actionable targets in cellular senescence.
Partial cellular reprogramming using three Yamanaka factors (OSK) successfully restored memory function in aged mice and Alzheimer's disease models by rejuvenating memory-encoding neurons while preserving their neuronal identity. This approach demonstrates that targeted reprogramming of engram cells can reverse age-related cognitive decline without causing dedifferentiation or memory loss.
ATG-18, a protein long associated with autophagy, extends lifespan through a mechanism independent of autophagy itself when the germline is removed. In the intestine, ATG-18 extends lifespan by interacting with PCK-2, an enzyme involved in glucose production, revealing a tissue-specific, non-autophagic pathway to longevity.
Iron accumulation drives a coordinated aging process termed ferro-aging, characterized by oxidative damage and cellular senescence across tissues. Vitamin C administration reversed aging markers and restored functional capacity in aged cynomolgus monkeys, suggesting a tractable intervention point in iron-dependent aging pathways.
A UK Biobank study of 272,500 participants links elevated blood tyrosine levels to reduced lifespan, with a stronger effect in men (approximately one year lost per standard deviation increase). Using Mendelian randomization to establish causality rather than mere association, the research suggests tyrosine acts as a causal factor in mortality risk, independent of phenylalanine.
TIM-3, an immune checkpoint protein, drives age-related immune dysfunction and contributes to neurodegeneration and brain tumors through promotion of immunosuppressive myeloid cells. Blocking TIM-3 represents a potential therapeutic approach to restore immune competence in central nervous system disease.
Protein misfolding drives over 100 diseases and accelerates aging-related decline. Origami Therapeutics is developing targeted protein degraders and conformation correctors that address root cause mechanisms rather than symptoms, with initial focus on neurodegenerative diseases including Huntington's, Alzheimer's, and Parkinson's.
